Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants
NCT07700329Phase 1Not yet recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2027
- Primary completion
- Feb 2027
01
Overview
Phase 1, randomised, double-blind trial of bms-986368 (2 cohorts), sponsored by Celgene Corporation. Primary endpoints: Maximum observed concentration, Time of maximum observed concentration and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
bms-986368
Beyond the preview
Go deeper on NCT07700329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07700329.